Read as PDF
Lund, Sweden, 22nd of May 2017 – Xintela
AB (publ) announces today that the company has signed a non-binding Memorandum
of Understanding with the leading European cell therapy company, CO.DON. The
parties intend to collaborate on the development of Xintela’s quality markers
for CO.DON’s next cell-based product and for the co-development of Xintela’s
stem cell product for the treatment of osteoarthritis.
The
Memorandum of Understanding follows from the positive results of the validation
of Xintela’s quality assurance assay, XACT™, which was carried out
together with CO.DON. It means the two companies will now take the next step
towards a deeper, product development-focused collaboration.
“Last year we completed a very
successful collaboration with CO.DON to validate Xintela’s markers for quality
assurance of CO.DON’s cartilage cells. CO.DON is one of the leading
regenerative medicine companies in Europe and we look forward to reaching
definitive agreements to start developing these new business opportunities”,
says Xintela's CEO Evy Lundgren-Åkerlund.
About CO.DON
CO.DON AG develops, produces and markets in Germany autologous cell therapies
for the minimally invasive repair of cartilage damage in joints following
traumatic or degenerative defects. CO.DON condrosphere® is a cell therapy
product that uses only the patient's own cartilage cells ("autologous
chondrocytes"). CO.DON condrosphere® has been approved by the German
federal agency PEI in accordance with Section 4b of the German Pharmaceuticals
Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain
European marketing authorisation. CO.DON condrosphere® has been used for more
than 10 years in over 150 clinics to treat more than 11,000 patients. In
Germany the statutory health insurance companies have paid for the treatment of
knee and hip joints since 2007 and for the treatment of vertebral joints since
2008. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN:
DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).
Further information can be found at www.ihre-zellzuechter.de or www.codon.de
Xintela
AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please
contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se
About
Xintela
Xintela AB (publ) is a Swedish biomedical
company active in the fields of regenerative medicine and cancer, with a focus
on cartilage damage and brain tumours. The key to Xintela's business is the
Company's patented marker technology, XINMARK™. Xintela's markers are specific
proteins which sit as "recognition flags" on certain cell
surfaces. The markers make it possible
to identify and quality assure cartilage cells and stem cells and also to
select a certain type of stem cells which can develop into cartilage cells.
Through this technology, Xintela can, in a unique way, quality assure stem
cells for the repair of damaged cartilage. The XINMARK™-technology makes it
also possible to direct antibody treatment to cells in glioblastoma brain
tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq
First North Stockholm since 22 March 2016. Xintela's Certified Adviser at
Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is information that Xintela AB (publ) is obliged to
make public pursuant to the EU Market Abuse Regulation. This information was
submitted for publication through the agency of the contact persons set out
above on 22 May 2017, at 14:00 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
CEO Evy Lundgren-Åkerlund presents the company at ProHearings Capital Market Day in Stockholm on June 1, 2023.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
